CA2634046A1 - Micrornas that regulate muscle cell proliferation and differentiation - Google Patents

Micrornas that regulate muscle cell proliferation and differentiation Download PDF

Info

Publication number
CA2634046A1
CA2634046A1 CA002634046A CA2634046A CA2634046A1 CA 2634046 A1 CA2634046 A1 CA 2634046A1 CA 002634046 A CA002634046 A CA 002634046A CA 2634046 A CA2634046 A CA 2634046A CA 2634046 A1 CA2634046 A1 CA 2634046A1
Authority
CA
Canada
Prior art keywords
mir
mirna
gene
myocyte
expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002634046A
Other languages
English (en)
French (fr)
Inventor
Da-Zhi Wang
Jianfu Chen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
University of North Carolina at Chapel Hill
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of North Carolina at Chapel Hill filed Critical University of North Carolina at Chapel Hill
Priority to CA2903764A priority Critical patent/CA2903764A1/en
Publication of CA2634046A1 publication Critical patent/CA2634046A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3517—Marker; Tag
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00—Production
    • C12N2330/10—Production naturally occurring

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA002634046A 2005-12-12 2006-12-12 Micrornas that regulate muscle cell proliferation and differentiation Abandoned CA2634046A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA2903764A CA2903764A1 (en) 2005-12-12 2006-12-12 Micrornas that regulate muscle cell proliferation and differentiation

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US74954405P 2005-12-12 2005-12-12
US60/749,544 2005-12-12
PCT/US2006/047255 WO2007070483A2 (en) 2005-12-12 2006-12-12 Micrornas that regulate muscle cell proliferation and differentiation

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA2903764A Division CA2903764A1 (en) 2005-12-12 2006-12-12 Micrornas that regulate muscle cell proliferation and differentiation

Publications (1)

Publication Number Publication Date
CA2634046A1 true CA2634046A1 (en) 2007-06-21

Family

ID=38163464

Family Applications (2)

Application Number Title Priority Date Filing Date
CA002634046A Abandoned CA2634046A1 (en) 2005-12-12 2006-12-12 Micrornas that regulate muscle cell proliferation and differentiation
CA2903764A Abandoned CA2903764A1 (en) 2005-12-12 2006-12-12 Micrornas that regulate muscle cell proliferation and differentiation

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA2903764A Abandoned CA2903764A1 (en) 2005-12-12 2006-12-12 Micrornas that regulate muscle cell proliferation and differentiation

Country Status (14)

Country Link
US (3) US8431542B2 (enExample)
EP (3) EP2671949A1 (enExample)
JP (3) JP2009519339A (enExample)
KR (2) KR101485071B1 (enExample)
CN (2) CN101448942B (enExample)
AU (1) AU2006326517B2 (enExample)
BR (1) BRPI0619755A2 (enExample)
CA (2) CA2634046A1 (enExample)
DK (1) DK1969125T3 (enExample)
ES (1) ES2387250T3 (enExample)
NZ (3) NZ569738A (enExample)
PL (1) PL1969125T3 (enExample)
PT (1) PT1969125E (enExample)
WO (1) WO2007070483A2 (enExample)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006107826A2 (en) 2005-04-04 2006-10-12 The Board Of Regents Of The University Of Texas System Micro-rna's that regulate muscle cells
CN101448942B (zh) 2005-12-12 2014-04-23 北卡罗来纳大学查珀尔希尔分校 调节肌细胞增殖和分化的microrna
EP2434017A3 (en) 2006-08-01 2012-09-05 Board of Regents of the University of Texas System Identification of a micro-RNA that activates expression of beta-myosin heavy chain
GB2440782A (en) * 2006-08-04 2008-02-13 Cesare Peschle Uses and compositions comprising miRNAs
HUE037173T2 (hu) 2006-08-08 2018-08-28 Univ Bonn Rheinische Friedrich Wilhelms 5'-Foszfát-oligonukleotidok szerkezete és alkalmazása
CA2728575A1 (en) 2007-06-29 2009-01-08 Boston Biomedical, Inc. Enabling the use of long dsrna for gene targeting in mammalian and other selected animal cells
WO2009018492A2 (en) * 2007-07-31 2009-02-05 The Board Of Regents Of The University Of Texas System Micro-rnas that control myosin expression and myofiber identity
ES2621161T3 (es) * 2007-07-31 2017-07-03 The Board Of Regents Of The University Of Texas System Familia de micro-ARN que modula la fibrosis y usos de la misma
CA2716343A1 (en) * 2008-02-21 2009-08-27 The Board Of Regents Of The University Of Texas System Micro-rnas that modulate smooth muscle proliferation and differentiation and uses thereof
CA2718520C (en) * 2008-03-17 2020-01-07 The Board Of Regents Of The University Of Texas System Identification of micro-rnas involved in neuromuscular synapse maintenance and regeneration
EP2297323A1 (en) 2008-05-21 2011-03-23 Hartmann, Gunther 5' triphosphate oligonucleotide with blunt end and uses thereof
AU2009257663B2 (en) * 2008-06-09 2014-06-26 New York Medical College Compositions comprising cardiac stem cells overexpressing specific microRNA and methods of their use in repairing damaged myocardium
GB0811715D0 (en) * 2008-06-26 2008-07-30 Angeletti P Ist Richerche Bio Therapeutic agents
MX2011008190A (es) 2009-02-04 2011-10-06 Univ Texas Direccionamiento dual de mir-208 y mir-499 en el tratamiento de trastornos cardiacos.
DK2427472T3 (en) 2009-05-05 2016-09-12 Miragen Therapeutics Lipophilic polynukleotidkonjugater
EP2435570A1 (en) * 2009-05-25 2012-04-04 Carola Ponzetto Differentiation therapy for sarcomas
US20130034850A1 (en) * 2010-02-26 2013-02-07 Natinal Center of Neurology and Psychiatry Marker for detecting myogenic disease and detection method using the same
KR20130069587A (ko) * 2010-04-08 2013-06-26 교토후고리츠다이가쿠호진 체액 유래 검체를 사용한 횡문근육종의 검출 방법
US9987309B2 (en) * 2010-07-08 2018-06-05 Duke University Direct reprogramming of cells to cardiac myocyte fate
KR101235256B1 (ko) * 2010-09-13 2013-02-21 서울대학교산학협력단 ｍｉＲＮＡ를 타겟으로 한 신경퇴행성 질환 치료
AU2011323085B2 (en) 2010-11-05 2014-10-30 Miragen Therapeutics Base modified oligonucleotides
EP2638158A4 (en) * 2010-11-11 2015-07-15 Univ Miami COMPOSITIONS, CELLS, KITS AND METHODS FOR AUTOLOGOUS STEM CELL THERAPY
US8642751B2 (en) 2010-12-15 2014-02-04 Miragen Therapeutics MicroRNA inhibitors comprising locked nucleotides
EP2508530A1 (en) 2011-03-28 2012-10-10 Rheinische Friedrich-Wilhelms-Universität Bonn Purification of triphosphorylated oligonucleotides using capture tags
CN103814131A (zh) * 2011-05-09 2014-05-21 格拉斯哥大学理事会 在肺动脉高血压的治疗中调控microrna的方法
US20140221464A1 (en) * 2011-07-01 2014-08-07 Board Of Regents, The University Of Texas System Compositions and Methods for Treating Skeletal Myopathy
EP2731422B1 (en) * 2011-07-12 2017-08-09 Mart Saarma miRNA antagonists for use in treating neurodegenerative disorders by increasing expression of GDNF
US9018188B2 (en) 2011-09-13 2015-04-28 Ottawa Hospital Research Institute MicroRNA inhibitors
US9428749B2 (en) * 2011-10-06 2016-08-30 The Board Of Regents, The University Of Texas System Control of whole body energy homeostasis by microRNA regulation
JP6208228B2 (ja) 2012-06-21 2017-10-04 ミラゲン セラピューティクス， インコーポレイテッド ロックド核酸モチーフを含むオリゴヌクレオチドベースの阻害剤
EP2712870A1 (en) 2012-09-27 2014-04-02 Rheinische Friedrich-Wilhelms-Universität Bonn Novel RIG-I ligands and methods for producing them
US9752143B2 (en) 2013-03-15 2017-09-05 MiRagen Therapeutics, Inc. Locked nucleic acid inhibitor of miR-145 and uses thereof
EP2970968B1 (en) 2013-03-15 2018-01-10 Miragen Therapeutics, Inc. Bridged bicyclic nucleosides
WO2014201254A1 (en) * 2013-06-12 2014-12-18 University Of Washington Through Its Center For Commercialization Methods for maturing cardiomyocytes and uses thereof
CN103710387B (zh) * 2013-12-25 2015-10-14 天津农学院 一种促进牛骨骼肌卫星细胞体外增殖的方法
JP6566536B2 (ja) * 2014-06-16 2019-08-28 国立大学法人山口大学 フォワードプライマー
CN104498497A (zh) * 2014-12-10 2015-04-08 山东农业大学 一种与奶山羊乳腺上皮细胞凋亡相关的miRNA及其在奶山羊育种中的应用
US10620109B2 (en) 2015-01-14 2020-04-14 Kyoto University Method for selecting skeletal muscle progenitor cell
EP3247716A4 (en) 2015-01-20 2018-10-17 Miragen Therapeutics, Inc. Mir-92 inhibitors and uses thereof
CN104877960B (zh) * 2015-06-01 2017-09-19 东北农业大学 miR‑2400显著促进牛骨骼肌卫星细胞增殖的生物功能
CN117757794A (zh) 2016-03-07 2024-03-26 美国政府(由卫生和人类服务部的部长所代表) 微小rna及其使用方法
CN105713972A (zh) * 2016-03-16 2016-06-29 上海中医药大学 miRNA在制备药物性心脏病生物标志物中的用途
CN106399473B (zh) * 2016-08-23 2019-12-06 南京大学 检测和评价力量训练效果的miRNA标志物或其组合及其应用
EP3527212A4 (en) * 2016-10-13 2020-05-06 National Center of Neurology and Psychiatry Myogenesis inducing agent
WO2018080658A1 (en) * 2016-10-27 2018-05-03 Aalborg University Therapeutic targeting of a microrna to treat duchenne muscular dystrophy
CN108324946B (zh) * 2017-01-20 2022-02-18 上海市东方医院 miRNA708、和/或301簇的微小RNA在改善心脏功能方面的应用
CN107096030A (zh) * 2017-03-20 2017-08-29 天津农学院 一种利用miR‑143抑制剂延缓小鼠失神经后肌肉萎缩的方法
WO2018187523A2 (en) * 2017-04-05 2018-10-11 University Of Cincinnati Promotion of cardiomyocyte proliferation and regenerative treatment of the heart by inhibition of microrna-128
WO2019035690A1 (ko) * 2017-08-18 2019-02-21 서울대학교병원 근육 질환 및 신경근육 질환 예방, 치료 또는 진단을 위한 miR-18b의 용도
KR102177130B1 (ko) 2017-08-18 2020-11-10 (주)큐라미스 근육 질환 및 신경근육 질환 예방, 치료 또는 진단을 위한 miR-18b의 용도
WO2019113432A1 (en) * 2017-12-08 2019-06-13 University Of Washington Methods and compositions for detecting and promoting cardiolipin remodeling and cardiomyocyte maturation and related methods of treating mitochondrial dysfunction
JP7318166B2 (ja) * 2018-03-14 2023-08-01 ベス イスラエル デアコネス メディカル センター マイクロｒｎａ２２の阻害剤
CN108690846A (zh) * 2018-04-17 2018-10-23 上海大学 抑制MiR-29b基因表达的应用
CN108823209B (zh) * 2018-07-18 2021-04-09 华中农业大学 骨骼肌特异性启动子及应用
AU2019333315B2 (en) 2018-08-30 2022-09-29 Tenaya Therapeutics, Inc. Cardiac cell reprogramming with myocardin and ASCL1
CN111041052B (zh) * 2019-12-30 2021-05-28 嘉兴学院 mir-206在抑制猪脂肪细胞内的甘油三酯生成以及瘦肉猪育种中的应用
CA3173567A1 (en) * 2020-03-02 2021-09-10 Tenaya Therapeutics, Inc. Gene vector control by cardiomyocyte-expressed micrornas
EP4127175A4 (en) 2020-04-02 2025-01-22 Mirecule, Inc. Targeted inhibition using engineered oligonucleotides
CN112266912A (zh) * 2020-10-22 2021-01-26 上海大学 靶向miR-29b的gRNA、AAV8-CRISPR/Cas9系统及其应用
WO2023034966A1 (en) * 2021-09-03 2023-03-09 The University Of North Carolina At Chapel Hill Compositions and methods of using the same for treating disorders associated with thymosin βeta 4
CN114480672B (zh) * 2022-02-22 2023-08-15 青岛农业大学 一种通过miR-145筛选高产肉率碱地黑牛的方法
CN114748497B (zh) * 2022-04-27 2024-10-18 广州市妇女儿童医疗中心 一种调控子宫肌收缩的miRNA分子miR-206及其应用
CN115181722B (zh) * 2022-08-30 2024-06-11 江苏农牧科技职业学院 一种鹅骨骼肌卫星细胞的体外分离和培养方法
CN117511884B (zh) * 2023-12-06 2024-06-11 中国农业科学院兰州畜牧与兽药研究所 Rtl1在抑制牦牛成肌细胞分化中的应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7803782B2 (en) * 2003-05-28 2010-09-28 Roche Madison Inc. Intravenous delivery of polynucleotides to cells in mammalian limb
US20050124566A1 (en) 2001-05-18 2005-06-09 Sirna Therapeutics, Inc. RNA interference mediated inhibition of myostatin gene expression using short interfering nucleic acid (siNA)
EP2390328A1 (en) * 2001-09-28 2011-11-30 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. MicroRNA molecules
US7781415B2 (en) * 2003-02-07 2010-08-24 Roche Madison Inc. Process for delivering sirna to cardiac muscle tissue
KR20050115231A (ko) * 2003-02-10 2005-12-07 내셔날 인스티튜트 오브 어드밴스드 인더스트리얼 사이언스 앤드 테크놀로지 포유동물 세포의 조절
SE521643C2 (sv) * 2003-02-26 2003-11-18 Scania Cv Publ Kraftöverföring med från en huvudväxel skild rangeväxel
EP2314688B1 (en) * 2004-11-12 2014-07-16 Asuragen, Inc. Methods and compositions involving miRNA and miRNA inhibitor molecules
WO2006107826A2 (en) 2005-04-04 2006-10-12 The Board Of Regents Of The University Of Texas System Micro-rna's that regulate muscle cells
WO2006113540A2 (en) 2005-04-14 2006-10-26 Duke University Use of ntrosylated hemoglobin
CN101448942B (zh) 2005-12-12 2014-04-23 北卡罗来纳大学查珀尔希尔分校 调节肌细胞增殖和分化的microrna

Also Published As

Publication number Publication date
ES2387250T3 (es) 2012-09-19
DK1969125T3 (da) 2012-07-23
CN101448942A (zh) 2009-06-03
EP1969125A4 (en) 2010-10-20
US20130225658A1 (en) 2013-08-29
AU2006326517A1 (en) 2007-06-21
CN101448942B (zh) 2014-04-23
JP2014094943A (ja) 2014-05-22
US9072764B2 (en) 2015-07-07
WO2007070483A9 (en) 2011-06-16
NZ602571A (en) 2014-03-28
EP2497827A1 (en) 2012-09-12
JP2009519339A (ja) 2009-05-14
NZ569738A (en) 2012-03-30
BRPI0619755A2 (pt) 2011-10-18
KR101485071B1 (ko) 2015-01-26
CA2903764A1 (en) 2007-06-21
US8431542B2 (en) 2013-04-30
NZ593688A (en) 2013-01-25
KR20140130562A (ko) 2014-11-10
PL1969125T3 (pl) 2012-11-30
JP5796027B2 (ja) 2015-10-21
US20130225665A1 (en) 2013-08-29
US20100292297A1 (en) 2010-11-18
AU2006326517B2 (en) 2013-02-21
JP5740460B2 (ja) 2015-06-24
KR20080080177A (ko) 2008-09-02
CN104027818A (zh) 2014-09-10
EP1969125A2 (en) 2008-09-17
EP1969125B1 (en) 2012-06-13
EP2671949A1 (en) 2013-12-11
JP2013126996A (ja) 2013-06-27
WO2007070483A2 (en) 2007-06-21
WO2007070483A3 (en) 2008-07-24
PT1969125E (pt) 2012-08-16

Similar Documents

Publication Publication Date Title
AU2006326517B2 (en) MicroRNAs that regulate muscle cell proliferation and differentiation
Williams Functional aspects of animal microRNAs
CA2977624C (en) Pharmaceutical composition for treating cancer comprising microrna as active ingredient
EP2208499A1 (en) Nucleic acid capable of regulating the proliferation of cell
EP2298359A1 (en) Nucleic acid capable of controlling degranulation of mast cell
AU2013202292B2 (en) MicroRNAs that regulate muscle cell proliferation and differentiation
HK1192280A (en) Micro-rna mir-145 that regulate muscle cell proliferation and differentiation
US20100305195A1 (en) microrna mediator of cardiomyopathy and heart failure
MX2008007552A (es) Microacidos ribonucleicos que regulan la proliferacion y diferenciacion de celulas musculares
Bril MicroRNA therapeutics in cardiovascular disease
Callis et al. miRNAs and Their Emerging Role in Cardiac Hypertrophy

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued

Effective date: 20160914